MedPath

Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds

Withdrawn
Conditions
Type 2 Diabetes
Diabetic Foot Ulcer
Diabetic Neuropathy
Registration Number
NCT02347709
Lead Sponsor
Winthrop University Hospital
Brief Summary

The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers. The secondary purpose will be to determine whether the degree of epidermal nerve fiber loss, the clinical examination, nerve conduction studies or the molecular profile correlates with appearance of lower extremity ulcers in patients with diabetes.

Detailed Description

Neuropathy is a common complication of diabetes seen in up to 43% of patients with diabetes. The relationship between neuropathy and diabetic lower extremity wounds is strong and in fact, 80% of patients with an existing diabetic foot ulcer (DFU) have neuropathy. Understanding the factors that contribute to the increased risk of wounds in patients with neuropathy is important in creating optimal strategies to reduce this risk.

Traditionally, the severity of diabetic neuropathy has been evaluated using the clinical exam and nerve conduction studies. More recently, new techniques such as intra-epidermal nerve fiber density have shown promise in evaluating neuropathy especially the small nerve fiber neuropathies that might affect pain sensation and autonomic function. There are also new molecular markers that may correlate with the risk of neuropathy that may also be useful in clinically evaluating the diabetic patient with neuropathy.

The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers. The secondary purpose will be to determine whether the degree of epidermal nerve fiber loss, the clinical examination, nerve conduction studies or the molecular profile correlates with appearance of lower extremity ulcers in patients with diabetes.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Age ≥ 18 years
  • Type 2 Diabetes defined as HgA1c ≥ 5.9%
  • Must be willing and able to provide written Informed Consent
Exclusion Criteria
  • Active osteomyelitis
  • Gangrene
  • Purulent drainage
  • Any experimental drugs applied topically or taken by mouth within 4 weeks of study entry
  • INR > 2.5

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measure the degree of loss of epidermal nerve fibers near a lower extremity diabetic wound using Intra-epidermal Nerve Fiber Density analysis.Three years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Winthrop University Hospital

🇺🇸

Mineola, New York, United States

Winthrop University Hospital
🇺🇸Mineola, New York, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.